Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 8 | 2025 | 548 | 2.020 |
Why?
|
| Pancreatectomy | 5 | 2025 | 58 | 1.750 |
Why?
|
| Adenocarcinoma | 4 | 2025 | 300 | 1.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2025 | 146 | 1.120 |
Why?
|
| Diagnostic Imaging | 2 | 2025 | 70 | 0.930 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2020 | 2 | 0.810 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2021 | 1 | 0.730 |
Why?
|
| Gallbladder | 1 | 2021 | 8 | 0.730 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 481 | 0.690 |
Why?
|
| Gastrostomy | 1 | 2020 | 8 | 0.640 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 29 | 0.630 |
Why?
|
| Patient Readmission | 1 | 2021 | 108 | 0.630 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 41 | 0.610 |
Why?
|
| Patient Transfer | 1 | 2017 | 43 | 0.520 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 191 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 433 | 0.440 |
Why?
|
| Humans | 20 | 2025 | 28851 | 0.370 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2020 | 42 | 0.340 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2020 | 5 | 0.330 |
Why?
|
| Ampulla of Vater | 2 | 2020 | 6 | 0.330 |
Why?
|
| Pancreatic Fistula | 2 | 2021 | 14 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2025 | 118 | 0.290 |
Why?
|
| Postoperative Complications | 2 | 2025 | 634 | 0.290 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 167 | 0.280 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2635 | 0.270 |
Why?
|
| Prognosis | 4 | 2025 | 811 | 0.250 |
Why?
|
| Bile Ducts | 1 | 2025 | 6 | 0.240 |
Why?
|
| Cholecystectomy | 1 | 2025 | 16 | 0.240 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 480 | 0.230 |
Why?
|
| Splenectomy | 1 | 2024 | 44 | 0.210 |
Why?
|
| Vaccines | 1 | 2024 | 35 | 0.200 |
Why?
|
| England | 1 | 2021 | 39 | 0.180 |
Why?
|
| Exosomes | 1 | 2023 | 96 | 0.170 |
Why?
|
| Middle Aged | 7 | 2025 | 7414 | 0.170 |
Why?
|
| Aged | 6 | 2025 | 5598 | 0.170 |
Why?
|
| Duodenal Neoplasms | 1 | 2020 | 6 | 0.160 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 3 | 0.160 |
Why?
|
| Receptors, Somatostatin | 1 | 2020 | 8 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 33 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 48 | 0.160 |
Why?
|
| Trauma Centers | 2 | 2018 | 125 | 0.160 |
Why?
|
| Intestine, Small | 1 | 2020 | 66 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 126 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2020 | 103 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2020 | 67 | 0.160 |
Why?
|
| Choledochal Cyst | 1 | 2019 | 5 | 0.150 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2019 | 19 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 100 | 0.150 |
Why?
|
| Patient Selection | 1 | 2020 | 150 | 0.150 |
Why?
|
| Leucovorin | 3 | 2025 | 19 | 0.150 |
Why?
|
| Fluorouracil | 3 | 2025 | 58 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 31 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2018 | 30 | 0.150 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 9 | 0.150 |
Why?
|
| Medically Uninsured | 1 | 2018 | 31 | 0.140 |
Why?
|
| Laparoscopy | 1 | 2020 | 156 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 80 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 133 | 0.140 |
Why?
|
| Risk Factors | 2 | 2021 | 2126 | 0.140 |
Why?
|
| Male | 8 | 2025 | 13921 | 0.140 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 38 | 0.140 |
Why?
|
| Spinal Cord Injuries | 1 | 2018 | 69 | 0.140 |
Why?
|
| Length of Stay | 1 | 2018 | 245 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2020 | 1280 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2020 | 250 | 0.130 |
Why?
|
| Female | 7 | 2025 | 15624 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 841 | 0.110 |
Why?
|
| Adult | 4 | 2025 | 8024 | 0.110 |
Why?
|
| Neoplasms | 1 | 2023 | 874 | 0.100 |
Why?
|
| Survival Rate | 2 | 2025 | 432 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 245 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 226 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2025 | 631 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 467 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 48 | 0.050 |
Why?
|
| Spleen | 1 | 2024 | 113 | 0.050 |
Why?
|
| Pancreas | 1 | 2024 | 63 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2065 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 30 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 56 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 2426 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 402 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2020 | 12 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 9 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 105 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2020 | 29 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 101 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 59 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 190 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 194 | 0.040 |
Why?
|
| Gastroenterology | 1 | 2019 | 15 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 288 | 0.040 |
Why?
|
| Contrast Media | 1 | 2019 | 96 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 1350 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2018 | 31 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 38 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2020 | 235 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 202 | 0.040 |
Why?
|
| Curriculum | 1 | 2020 | 303 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 518 | 0.030 |
Why?
|
| Oklahoma | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 2833 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 3193 | 0.020 |
Why?
|